The prevalence and prophylaxis of gout in England
- PMID: 7636517
- DOI: 10.1016/0895-4356(94)00244-k
The prevalence and prophylaxis of gout in England
Abstract
The prevalence of gout in England was reported as having nearly doubled in the 1970s to about 3 per 1000, and it is possible that it has continued to increase. There may also have been some change in the level of prophylactic therapy compared with the 44.8% recorded in 1979. In this study, data were provided from their morbidity registers by 40 volunteer practices with a combined population of over 300,000 patients. Analyses of prevalence by age and sex, and of the extent of prophylaxis were made. The male:female ratio and the increase with age found were in line with earlier work, but overall prevalence was much higher at almost 10 per 1000. There was considerable inter-practice variation: 20% of this could be accounted for by the age and sex structure of the practice populations, but neither economic status nor broad geographical factors appeared to be significant, and it did not appear to be due to variation between practices in the level of special interest in gout. Prophylactic therapy--almost entirely allopurinol--was being prescribed for 48% of the sufferers; though practices varied widely in their propensity to give it, as a group the amount of allopurinol they used was close to the national average. The increase found in the prevalence of gout may be related to an increase in obesity in the population.
Similar articles
-
An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population.J Rheumatol. 2015 Sep;42(9):1702-7. doi: 10.3899/jrheum.150310. Epub 2015 Aug 1. J Rheumatol. 2015. PMID: 26233513
-
Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations.Ann Rheum Dis. 2007 Oct;66(10):1311-5. doi: 10.1136/ard.2007.070755. Epub 2007 May 15. Ann Rheum Dis. 2007. PMID: 17504843 Free PMC article.
-
Rates of adherence and persistence with allopurinol therapy among gout patients in Israel.Rheumatology (Oxford). 2013 Jun;52(6):1126-31. doi: 10.1093/rheumatology/kes431. Epub 2013 Feb 7. Rheumatology (Oxford). 2013. PMID: 23392592
-
Managing gout: there's more we can do.J Fam Pract. 2014 Dec;63(12):707-13. J Fam Pract. 2014. PMID: 25486309 Review. No abstract available.
-
[Gout and hyperuricemia today: prevalence, risk factors, features in the elderly].Adv Gerontol. 2012;25(3):540-4. Adv Gerontol. 2012. PMID: 23289237 Review. Russian.
Cited by
-
Reduced Risk of Sepsis and Related Mortality in Chronic Kidney Disease Patients on Xanthine Oxidase Inhibitors: A National Cohort Study.Front Med (Lausanne). 2022 Jan 31;8:818132. doi: 10.3389/fmed.2021.818132. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35174186 Free PMC article.
-
Manifestations of metabolic syndrome associated with male gout in different age strata.Clin Rheumatol. 2007 Sep;26(9):1453-7. doi: 10.1007/s10067-006-0527-4. Epub 2007 Jan 26. Clin Rheumatol. 2007. PMID: 17256101
-
Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study.Ann Rheum Dis. 2015 Apr;74(4):661-7. doi: 10.1136/annrheumdis-2013-204463. Epub 2014 Jan 15. Ann Rheum Dis. 2015. PMID: 24431399 Free PMC article.
-
Difficult-to-treat gouty arthritis: a disease warranting better management.Drugs. 2011 Jul 30;71(11):1413-39. doi: 10.2165/11592290-000000000-00000. Drugs. 2011. PMID: 21812506 Review.
-
Gout.BMJ Clin Evid. 2011 May 17;2011:1120. BMJ Clin Evid. 2011. PMID: 21575286 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical